Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic expos... Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Show more
- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025...
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.45 | -14.0776699029 | 10.3 | 10.6237 | 8.65 | 2175746 | 9.42569543 | CS |
4 | -0.11 | -1.22767857143 | 8.96 | 10.6237 | 8.35 | 1815403 | 9.24578913 | CS |
12 | 3.06 | 52.8497409326 | 5.79 | 10.6237 | 4.55 | 2806686 | 8.0338528 | CS |
26 | 4.72 | 114.285714286 | 4.13 | 10.6237 | 3.95 | 1846179 | 7.25758982 | CS |
52 | 6.92 | 358.549222798 | 1.93 | 10.6237 | 1.79 | 1720760 | 5.95119596 | CS |
156 | -4.97 | -35.9623733719 | 13.82 | 13.98 | 0.4995 | 846873 | 4.63594495 | CS |
260 | -6.1 | -40.8026755853 | 14.95 | 57.39 | 0.4995 | 566365 | 7.28973211 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.